Enliven Therapeutics (ELVN) News Today $22.00 +0.53 (+2.45%) As of 01:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Down - Here's What HappenedEnliven Therapeutics (NASDAQ:ELVN) Shares Gap Down - Here's WhyFebruary 13, 2025 | marketbeat.comEnliven Therapeutics COO Anish Patel sells $146,205 in stockFebruary 11, 2025 | msn.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $146,207.31 in StockFebruary 11, 2025 | insidertrades.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells 6,667 Shares of StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,667 shares of the business's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $21.93, for a total transaction of $146,207.31. Following the completion of the transaction, the chief operating officer now owns 329,977 shares in the company, valued at approximately $7,236,395.61. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.February 10, 2025 | marketbeat.comEnliven Therapeutics CFO sells $22,524 in stockFebruary 8, 2025 | msn.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $22,520.00 in StockFebruary 8, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,000 SharesEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 1,000 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $22.52, for a total transaction of $22,520.00. Following the completion of the transaction, the chief financial officer now owns 13,000 shares in the company, valued at $292,760. This trade represents a 7.14 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.February 7, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $70,167.50 in StockJanuary 30, 2025 | insidertrades.comEnliven Therapeutics CFO sells $70,177 in stockJanuary 29, 2025 | msn.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 3,250 Shares of StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $21.59, for a total transaction of $70,167.50. Following the sale, the chief financial officer now directly owns 13,000 shares of the company's stock, valued at approximately $280,670. This trade represents a 20.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.January 29, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading Volume - Here's WhyEnliven Therapeutics (NASDAQ:ELVN) Sees Strong Trading Volume - Time to Buy?January 24, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Trading 11.3% Higher - Here's WhyEnliven Therapeutics (NASDAQ:ELVN) Trading 11.3% Higher - Still a Buy?January 15, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading Volume - Should You Buy?Enliven Therapeutics (NASDAQ:ELVN) Sees Large Volume Increase - Here's WhyJanuary 14, 2025 | marketbeat.comBarclays PLC Acquires 42,012 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Barclays PLC lifted its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 295.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,217 shares of the company's stock after pJanuary 13, 2025 | marketbeat.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells 21,700 Shares of StockJanuary 11, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $524,706.00 in StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 21,700 shares of the company's stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $24.18, for a total transaction of $524,706.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.January 10, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Shares Down 9.8% - Here's WhyEnliven Therapeutics (NASDAQ:ELVN) Stock Price Down 9.8% - Time to Sell?January 10, 2025 | marketbeat.comBenjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockJanuary 8, 2025 | insidertrades.comEnliven Therapeutics: Still Too Early To Pay This MuchJanuary 7, 2025 | seekingalpha.comEnliven's Early Data Stands Out From PeersJanuary 7, 2025 | seekingalpha.comJane Street Group LLC Sells 22,212 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Jane Street Group LLC lessened its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 41.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 30,793 shares of the company's stock after selling 22,212 shares during theJanuary 3, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Shares Up 7.6% - Here's What HappenedEnliven Therapeutics (NASDAQ:ELVN) Shares Up 7.6% - Time to Buy?January 2, 2025 | marketbeat.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 900 Shares of StockJanuary 1, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,350 SharesEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $22.15, for a total transaction of $74,202.50. The sale was disclosed in a filing with the SEC, which is available through this link.December 31, 2024 | marketbeat.comGeode Capital Management LLC Boosts Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Geode Capital Management LLC increased its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 9.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 750,208 shares of the company's stock after buyDecember 29, 2024 | marketbeat.comBarclays PLC Has $1.44 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Barclays PLC lifted its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 295.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 56,217 shares of the company's stock after buyingDecember 29, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Trading Down 2.9% - Should You Sell?Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 2.9% - What's Next?December 24, 2024 | marketbeat.comWellington Management Group LLP Purchases 36,267 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Wellington Management Group LLP grew its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 107.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 70,170 shares of the company's stock after buying an additionDecember 19, 2024 | marketbeat.comLord Abbett & CO. LLC Takes Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Lord Abbett & CO. LLC purchased a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 321,055 shares of the company's stock, valued at approximateDecember 17, 2024 | marketbeat.comBTIG Initiates Coverage of Enliven Therapeutics (ELVN) with Buy RecommendationDecember 13, 2024 | msn.comEnliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at BTIG ResearchBTIG Research initiated coverage on Enliven Therapeutics in a research note on Friday. They issued a "buy" rating and a $42.00 target price on the stock.December 13, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Boosts Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Charles Schwab Investment Management Inc. lifted its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 10.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 255,277 shares of the company's stockDecember 12, 2024 | marketbeat.comPromising Market Potential for Enliven Therapeutics’ ELVN-001 in Post-Asciminib CML Treatment LandscapeDecember 10, 2024 | markets.businessinsider.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by Janus Henderson Group PLCJanus Henderson Group PLC lifted its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 43.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,041,724 shares of the company'sDecember 7, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Trading 6.8% Higher - Still a Buy?Enliven Therapeutics (NASDAQ:ELVN) Shares Up 6.8% - Here's WhyDecember 6, 2024 | marketbeat.comRA Capital Management L.P. Reduces Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)RA Capital Management L.P. decreased its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 50.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,061,233 shares of the coDecember 5, 2024 | marketbeat.comPatient Square Capital LP Makes New Investment in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Patient Square Capital LP purchased a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 90,572 shares of the company's stock, valued at approximately $2,313,000. Enliven TherapeDecember 4, 2024 | marketbeat.comWalleye Capital LLC Takes $2.54 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Walleye Capital LLC bought a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 99,416 shares of the company's stock, valued at approximately $2,539,000. Walleye CapitalDecember 4, 2024 | marketbeat.comFmr LLC Buys 601,611 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Fmr LLC lifted its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 10.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,296,179 shares of the company's stock after purchaDecember 4, 2024 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $130,672.50 in StockDecember 3, 2024 | insidertrades.comEnliven Therapeutics (NASDAQ:ELVN) Stock Price Down 3% - Here's WhyEnliven Therapeutics (NASDAQ:ELVN) Shares Down 3% - Here's WhyNovember 29, 2024 | marketbeat.comAlly Bridge Group NY LLC Makes New $6 Million Investment in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Ally Bridge Group NY LLC bought a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 234,856 shares of the compaNovember 28, 2024 | marketbeat.comAcuta Capital Partners LLC Sells 101,330 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Acuta Capital Partners LLC lessened its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 25.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 296,368 shares of the company's stock after selNovember 28, 2024 | marketbeat.comShort Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Increases By 6.1%Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 6,910,000 shares, a growth of 6.1% from the October 15th total of 6,510,000 shares. Approximately 23.8% of the company's stock are short sold. Based on an average trading volume of 236,300 shares, the days-to-cover ratio is presently 29.2 days.November 19, 2024 | marketbeat.comFirst Turn Management LLC Has $13.67 Million Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)First Turn Management LLC increased its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 29.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 535,092 shares oNovember 19, 2024 | marketbeat.comPromising Clinical Developments and Strategic Positioning Drive Buy Rating for Enliven TherapeuticsNovember 15, 2024 | markets.businessinsider.comEnliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business UpdateNovember 15, 2024 | finanznachrichten.deEnliven Therapeutics Reports Q3 Results and Clinical ProgressNovember 15, 2024 | markets.businessinsider.comEnliven Therapeutics: Strategic Positioning and Promising Developments Justify Buy RatingNovember 15, 2024 | markets.businessinsider.comEnliven Therapeutics (NASDAQ:ELVN) Given New $40.00 Price Target at Robert W. BairdRobert W. Baird raised their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the company an "outperform" rating in a report on Friday.November 15, 2024 | marketbeat.com Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address ELVN Media Mentions By Week ELVN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELVN News Sentiment▼0.250.60▲Average Medical News Sentiment ELVN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELVN Articles This Week▼04▲ELVN Articles Average Week Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ultragenyx Pharmaceutical News Today Avidity Biosciences News Today SpringWorks Therapeutics News Today ADMA Biologics News Today Organon & Co. News Today Biohaven News Today Alvotech News Today PTC Therapeutics News Today Arcellx News Today Rhythm Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELVN) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELVN Stock Alerts